ClinVar Miner

Submissions for variant NM_170784.3(MKKS):c.7C>T (p.Arg3Cys)

gnomAD frequency: 0.00004  dbSNP: rs779042065
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001228518 SCV001400919 uncertain significance Bardet-Biedl syndrome; McKusick-Kaufman syndrome 2022-08-17 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 3 of the MKKS protein (p.Arg3Cys). This variant is present in population databases (rs779042065, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with MKKS-related conditions. ClinVar contains an entry for this variant (Variation ID: 955812). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0". The cysteine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
GeneDx RCV001806063 SCV002050410 uncertain significance not provided 2021-06-30 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 27535533)
Genetic Services Laboratory, University of Chicago RCV001819927 SCV002071392 uncertain significance not specified 2021-03-08 criteria provided, single submitter clinical testing DNA sequence analysis of the MKKS gene demonstrated a sequence change, c.7C>T, in exon 3 that results in an amino acid change, p.Arg3Cys. This sequence change has been described in gnomAD with a population frequency of 0.0089% (dbSNP rs779042065). The p.Arg3Cys change affects a highly conserved amino acid residue located in a domain of the MKKS protein that is not known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Arg3Cys substitution. This sequence change does not appear to have been previously described in patients with MKKS-related disorders Due to the lack of sufficient evidences, the clinical significance of the p.Arg3Cys change remains unknown at this time.
SN ONGC Dept of Genetics and Molecular biology Vision Research Foundation RCV003224532 SCV003920698 uncertain significance Bardet-Biedl syndrome 2023-06-02 criteria provided, single submitter research
PreventionGenetics, part of Exact Sciences RCV003398978 SCV004120256 uncertain significance MKKS-related condition 2023-12-05 criteria provided, single submitter clinical testing The MKKS c.7C>T variant is predicted to result in the amino acid substitution p.Arg3Cys. To our knowledge, this variant has not been reported in the literature in individuals with MKKS-related disorders. This variant is reported in 0.016% of alleles in individuals of South Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.